Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9612906 | 0.79 | CYP2A6 (0.36) | PTGS2HTR1ASLC6A2SLC6A4CNR2 | |
| SCHEMBL9128602 | 0.78 | PTGS2 (0.41) | PTGS2ALDH1A1OPRL1 | |
| SCHEMBL10634854 | 0.77 | KDM4E (0.53) | ALDH1A1GAA | |
| SCHEMBL2322176 | 0.77 | CHRNB2 (0.42) | HTR1ASLC6A2SLC6A4ADRA1ATNKS2 | |
| SCHEMBL10634926 | 0.77 | KDM4E (0.53) | ALDH1A1GAA | |
| SCHEMBL8036544 | 0.77 | PTGS2 (0.46) | PTGS2HTR1ASLC6A2SLC6A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10630457 | 0.76 | KDM4E (0.51) | ALDH1A1GAA | |
| SCHEMBL24041236 | 0.76 | GAA (0.41) | HTR1ASLC6A2SLC6A4ADRA1AOPRL1 | |
| SCHEMBL21864347 | 0.76 | ADRA1A (0.40) | HTR1ASLC6A2SLC6A4ADRA1AOPRL1 | |
| SCHEMBL2084224 | 0.75 | CYP11B2 (0.43) | PTGS2HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4540258-B1 | RUTHENIUM COMPLEXES AND THEIR USES IN CHEMICAL REACTIONS | UNIV MANCHESTER (GB) | 2026-04-15 | — | — | EP | disclosed |
| US-20250242335-A1 | CATALYST | UNIV MANCHESTER (GB) | 2025-07-31 | — | — | US | disclosed |
| EP-4540258-A1 | CATALYST | The University of Manchester (GB) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023247563-A1 | CATALYST | THE UNIVERSITY OF MANCHESTER (GB) | 2023-12-28 | — | — | WO | disclosed |
| WO-2019215427-A1 | PROCESS FOR FORMING A CARBON-CARBON BOND | THE UNIVERSITY OF MANCHESTER (GB) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242335-A1 | CATALYST | CYP1A1, CYP1A2, CYP2B6 | PTGS2 1388/4885HTR1A 2186/4885SLC6A2 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.